Peanut Allergy clinical trials at UCSF
2 in progress, 0 open to eligible people
Showing trials for
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Sorry, accepting new patients by invitation only
Open-label, follow-up study for subjects who completed the EPITOPE study.
San Francisco, California and other locations
Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
Sorry, in progress, not accepting new patients
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
San Francisco, California and other locations
Last updated: